Talazoparib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 0.25 mg, 1 mg
Reference Brands: Talzenna (USA/EU)
Category:
Oncology Cancer Care
Talazoparib is available in Capsules
and strengths such as 0.25 mg, 1 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Talazoparib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Talazoparib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Talazoparib tosylate is a targeted anticancer medication belonging to the class of poly ADP-ribose polymerase (PARP) inhibitors. It is used for the treatment of adults with HER2-negative, locally advanced or metastatic breast cancer who carry germline BRCA1 or BRCA2 gene mutations. It is also used in combination with enzalutamide for certain patients with metastatic castration-resistant prostate cancer that have homologous recombination repair (HRR) gene mutations and whose disease has progressed despite testosterone-lowering therapy.
Talazoparib works by blocking the PARP enzyme, which plays a key role in repairing damaged DNA inside cells. Cancer cells that already have defects in DNA repair pathways, such as BRCA-mutated cells, become unable to repair genetic damage when PARP is inhibited, leading to cell death. This mechanism makes talazoparib an example of precision oncology based on genetic profiling. It is administered orally and marketed under the brand name Talzenna by Pfizer. Clinical studies have shown meaningful benefit in selected patients, and treatment is given under oncology specialist supervision with regular safety monitoring.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing